156 related articles for article (PubMed ID: 22512815)
1. The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease.
Kontzias A; Efthimiou P
Semin Arthritis Rheum; 2012 Oct; 42(2):201-5. PubMed ID: 22512815
[TBL] [Abstract][Full Text] [Related]
2. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.
Kedor C; Listing J; Zernicke J; Weiß A; Behrens F; Blank N; Henes JC; Kekow J; Rubbert-Roth A; Schulze-Koops H; Seipelt E; Specker C; Feist E
Ann Rheum Dis; 2020 Aug; 79(8):1090-1097. PubMed ID: 32404342
[TBL] [Abstract][Full Text] [Related]
3. Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options.
Bindoli S; Baggio C; Doria A; Sfriso P
Drugs; 2024 Mar; 84(3):257-274. PubMed ID: 38441807
[TBL] [Abstract][Full Text] [Related]
4. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.
Saper VE; Ombrello MJ; Tremoulet AH; Montero-Martin G; Prahalad S; Canna S; Shimizu C; Deutsch G; Tan SY; Remmers EF; Monos D; Hahn T; Phadke OK; Cassidy E; Ferguson I; Mallajosyula V; Xu J; Rosa Duque JS; Chua GT; Ghosh D; Szymanski AM; Rubin D; Burns JC; Tian L; Fernandez-Vina MA; Mellins ED; Hollenbach JA; ;
Ann Rheum Dis; 2022 Mar; 81(3):406-415. PubMed ID: 34789453
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.
Hoffmann MC; Cavalli G; Fadle N; Cantoni E; Regitz E; Fleser O; Klemm P; Zaks M; Stöger E; Campochiaro C; Tomelleri A; Baldissera E; Bittenbring JT; Zimmer V; Pfeifer J; Fischer Y; Preuss KD; Bewarder M; Thurner B; Fuehner S; Foell D; Dagna L; Kessel C; Thurner L
J Clin Immunol; 2024 Jan; 44(2):45. PubMed ID: 38231276
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Metaanalysis of Pharmacological Interventions in Adult-Onset Still Disease and the Role of Biologic Disease-Modifying Antirheumatic Drugs.
Ruscitti P; McGonagle D; Garcia VC; Rabijns H; Toennessen K; Chappell M; Edwards M; Miller P; Hansell N; Moss J; Graziadio S; Feist E
J Rheumatol; 2024 May; 51(5):442-451. PubMed ID: 38302170
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Biological Drugs in Still's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Kilic B; Ozturk A; Karup S; Hacioglu E; Ugurlu S
Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38775654
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's Disease.
Vitale A; Caggiano V; Sfikakis PP; Dagna L; Lopalco G; Ragab G; La Torre F; Almaghlouth IA; Maggio MC; Sota J; Tufan A; Hinojosa-Azaola A; Iannone F; Loconte R; Laskari K; Direskeneli H; Ruscitti P; Morrone M; Mayrink Giardini HA; Panagiotopoulos A; Di Cola I; Martín-Nares E; Monti S; De Stefano L; Kardas RC; Duran R; Campochiaro C; Tomelleri A; Alabdulkareem AM; Gaggiano C; Tarsia M; Bartoloni E; Romeo M; Hussein MA; Laymouna AH; Parente de Brito Antonelli I; Dagostin MA; Fotis L; Bindoli S; Navarini L; Alibaz-Oner F; Sevik G; Frassi M; Ciccia F; Iacono D; Crisafulli F; Portincasa P; Jaber N; Kawakami-Campos PA; Wiesik-Szewczyk E; Iagnocco A; Simonini G; Sfriso P; Balistreri A; Giacomelli R; Conti G; Frediani B; Fabiani C; Cantarini L
Front Med (Lausanne); 2023; 10():1256243. PubMed ID: 38148914
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.
Cabrera SM; Wang X; Chen YG; Jia S; Kaldunski ML; Greenbaum CJ; ; Mandrup-Poulsen T; ; Hessner MJ
Eur J Immunol; 2016 Apr; 46(4):1030-46. PubMed ID: 26692253
[TBL] [Abstract][Full Text] [Related]
10. [Use of anti-IL-1 drugs during pregnancy].
Faure-Bardon V; Beghin D; Latour M; Coulm B; Vauzelle C; Elefant E; Marin B
Gynecol Obstet Fertil Senol; 2024 Apr; ():. PubMed ID: 38621625
[TBL] [Abstract][Full Text] [Related]
11. Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review).
Junge G; Mason J; Feist E
Semin Arthritis Rheum; 2017 Oct; 47(2):295-302. PubMed ID: 28757235
[TBL] [Abstract][Full Text] [Related]
12. Adult-onset Still's disease.
Gerfaud-Valentin M; Jamilloux Y; Iwaz J; Sève P
Autoimmun Rev; 2014 Jul; 13(7):708-22. PubMed ID: 24657513
[TBL] [Abstract][Full Text] [Related]
13. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat N; Horneff G; Brik R; McCann L; Kasapcopur O; Rutkowska-Sak L; Schneider R; Berkun Y; Calvo I; Erguven M; Goffin L; Hofer M; Kallinich T; Oliveira SK; Uziel Y; Viola S; Nistala K; Wouters C; Cimaz R; Ferrandiz MA; Flato B; Gamir ML; Kone-Paut I; Grom A; Magnusson B; Ozen S; Sztajnbok F; Lheritier K; Abrams K; Kim D; Martini A; Lovell DJ; ;
N Engl J Med; 2012 Dec; 367(25):2396-406. PubMed ID: 23252526
[TBL] [Abstract][Full Text] [Related]
14. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
Rossi-Semerano L; Fautrel B; Wendling D; Hachulla E; Galeotti C; Semerano L; Touitou I; Koné-Paut I;
Orphanet J Rare Dis; 2015 Feb; 10():19. PubMed ID: 25758134
[TBL] [Abstract][Full Text] [Related]
15. [Pathophysiology, subtypes, and treatments of adult-onset Still's disease: An update].
Gerfaud-Valentin M; Sève P; Hot A; Broussolle C; Jamilloux Y
Rev Med Interne; 2015 May; 36(5):319-27. PubMed ID: 25466605
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients.
Ortiz-Sanjuán F; Blanco R; Calvo-Rio V; Narvaez J; Rubio Romero E; Olivé A; Castañeda S; Gallego Flores A; Hernández MV; Mata C; Ros Vilamajo I; Sifuentes Giraldo WA; Caracuel MA; Freire M; Gómez Arango C; Llobet J; Manrique Arija S; Marras C; Moll-Tuduri C; Plasencia-Rodriguez C; Roselló R; Urruticoechea A; Velloso-Feijoo ML; Del Blanco J; González-Vela MC; Rueda-Gotor J; Pina T; Loricera J; González-Gay MA
Arthritis Rheumatol; 2014 Jun; 66(6):1659-65. PubMed ID: 24515813
[TBL] [Abstract][Full Text] [Related]
17. Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations.
Lo Gullo A; Caruso A; Pipitone N; Macchioni P; Pazzola G; Salvarani C
Joint Bone Spine; 2014 Jul; 81(4):376-7. PubMed ID: 24462130
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
Feist E; Quartier P; Fautrel B; Schneider R; Sfriso P; Efthimiou P; Cantarini L; Lheritier K; Leon K; Karyekar CS; Speziale A
Clin Exp Rheumatol; 2018; 36(4):668-675. PubMed ID: 29533755
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of refractory adult-onset still disease with canakinumab: a case report.
Barsotti S; Neri R; Iacopetti V; d'Ascanio A; Talarico R; Tripoli A; Bombardieri S
J Clin Rheumatol; 2014 Mar; 20(2):121. PubMed ID: 24561423
[No Abstract] [Full Text] [Related]
20. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity.
Nirmala N; Brachat A; Feist E; Blank N; Specker C; Witt M; Zernicke J; Martini A; Junge G
Pediatr Rheumatol Online J; 2015 Nov; 13():50. PubMed ID: 26589963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
